Published in Ann Oncol on May 22, 2008
Trabectedin in soft tissue sarcomas. Mar Drugs (2015) 0.87
Role of trabectedin in the treatment of soft tissue sarcoma. Onco Targets Ther (2009) 0.86
Pegylated liposomal doxorubicin in the management of ovarian cancer. Ther Clin Risk Manag (2010) 0.85
Clinical trials with pegylated liposomal Doxorubicin in the treatment of ovarian cancer. J Drug Deliv (2013) 0.83
Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Invest New Drugs (2010) 0.81
Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres. Mol Cancer Ther (2010) 0.79
Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. Adv Ther (2016) 0.79
Challenging issues in molecular-targeted therapy. Ther Clin Risk Manag (2009) 0.76
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies. Cancer Chemother Pharmacol (2015) 0.75
New developments in treatment of ovarian carcinoma: focus on trabectedin. Cancer Manag Res (2010) 0.75
Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence. Onco Targets Ther (2014) 0.75
Emesis and nausea related to single agent trabectedin in ovarian cancer patients: a sub-study of the MITO15 project. Support Care Cancer (2017) 0.75
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst (2000) 133.74
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol (2005) 2.39
Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol (2004) 2.15
Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol (2004) 2.08
Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med (2001) 2.04
Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer (2001) 2.02
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer (2001) 1.99
Phase II trial of pegylated-liposomal doxorubicin (Doxil) in sarcoma. Cancer Invest (2003) 1.83
DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry (1996) 1.73
Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol (1991) 1.62
Ecteinascidin 743: a minor groove alkylator that bends DNA toward the major groove. J Med Chem (1999) 1.48
Interference of transcriptional activation by the antineoplastic drug ecteinascidin-743. Proc Natl Acad Sci U S A (2000) 1.34
Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol (2001) 1.33
Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. J Clin Oncol (2001) 1.26
Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res (1998) 1.21
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res (2001) 1.15
In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol (1998) 1.14
Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res (2001) 1.10
Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol (2003) 1.08
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res (2002) 1.07
Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res (2001) 1.07
Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs (2004) 1.02
Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol (2001) 1.02
A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer. Br J Cancer (2006) 1.00
Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer (2003) 0.97
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res (2000) 0.96
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer (2003) 0.95
High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer. Ann Oncol (1999) 0.95
A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clin Cancer Res (2005) 0.93
Population pharmacokinetics and pharmacodynamics of pegylated-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. Clin Pharmacol Ther (1997) 0.92
Hepatic stellate cell immunodetection and cirrhotic evolution of viral hepatitis in liver allografts. Hepatology (1997) 0.89
Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer. Anticancer Drugs (2000) 0.86
A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs (2002) 0.85
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs (2002) 0.80
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood (1997) 4.97
The indeterminate gene encodes a zinc finger protein and regulates a leaf-generated signal required for the transition to flowering in maize. Cell (1998) 3.18
Agreement of Medicare claims and tumor registry data for assessment of cancer-related treatment. Med Care (2000) 2.36
The sensitivity of Medicare claims data for case ascertainment of six common cancers. Med Care (1999) 2.21
Quality of life for children with fecal incontinence after surgically corrected anorectal malformation. J Pediatr Surg (2000) 2.17
Partial purification of a nuclear protein that binds to the CCAAT box of the mouse alpha 1-globin gene. Mol Cell Biol (1986) 2.04
Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry (2000) 2.03
The fasciated ear2 gene encodes a leucine-rich repeat receptor-like protein that regulates shoot meristem proliferation in maize. Genes Dev (2001) 1.97
Pathologic predictors of early local recurrence in Stage I and II breast cancer treated by primary radiation therapy. Cancer (1984) 1.95
Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.87
Surgery for colorectal cancer: Race-related differences in rates and survival among Medicare beneficiaries. Am J Public Health (1996) 1.83
Stimulation of p300-mediated transcription by the kinase MEKK1. J Biol Chem (2001) 1.72
Cloning of four cyclins from maize indicates that higher plants have three structurally distinct groups of mitotic cyclins. Proc Natl Acad Sci U S A (1994) 1.68
Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother (2000) 1.67
Bacterial Peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem (2005) 1.65
Alcohol-related hospitalizations of elderly people. Prevalence and geographic variation in the United States. JAMA (1993) 1.61
Patterns of endoscopic follow-up after surgery for nonmetastatic colorectal cancer. Gastrointest Endosc (2000) 1.59
Identification of sequences within the murine granulocyte-macrophage colony-stimulating factor mRNA 3'-untranslated region that mediate mRNA stabilization induced by mitogen treatment of EL-4 thymoma cells. J Biol Chem (1991) 1.54
Age- and joint-specific risk of initial heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. Clin Orthop Relat Res (1994) 1.54
The utility of Medicare claims data for measuring cancer stage. Med Care (1999) 1.54
Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J Clin Oncol (1996) 1.53
Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr (1995) 1.48
Resistance of Streptococcus pneumoniae to deformylase inhibitors is due to mutations in defB. Antimicrob Agents Chemother (2001) 1.41
Torsional ultrasound modality for hard nucleus phacoemulsification cataract extraction. Br J Ophthalmol (2008) 1.40
Fractionated total-body irradiation preceding high-dose cytosine arabinoside as a preparative regimen for bone marrow transplantation in children with acute leukemia. Med Pediatr Oncol (1995) 1.39
Molecular markers and stem-cell transplants: are they made for each other? J Clin Oncol (1995) 1.38
A common protein binds to two silencers 5' to the human beta-globin gene. Nucleic Acids Res (1989) 1.36
Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endod (1996) 1.35
Cocaine-induced cortical microischemia in the rodent brain: clinical implications. Mol Psychiatry (2011) 1.31
The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology (1999) 1.31
DNA affinity labeling of adenovirus type 2 upstream promoter sequence-binding factors identifies two distinct proteins. Mol Cell Biol (1988) 1.27
Lumbar spine surgery and mortality among Medicare beneficiaries, 1986. Am J Public Health (1994) 1.27
Emergence of a new GII.17 norovirus variant in patients with acute gastroenteritis in Jiangsu, China, September 2014 to March 2015. Euro Surveill (2015) 1.26
Limited human-to-human transmission of avian influenza A(H7N9) virus, Shanghai, China, March to April 2013. Euro Surveill (2014) 1.25
Nucleosome disruption precedes transcription and is largely limited to the transcribed domain of globin genes in murine erythroleukemia cells. J Mol Biol (1985) 1.24
Liver-specific microRNA-122 target sequences incorporated in AAV vectors efficiently inhibits transgene expression in the liver. Gene Ther (2010) 1.21
Binding of sequence-specific proteins to the adenosine- plus uridine-rich sequences of the murine granulocyte/macrophage colony-stimulating factor mRNA. Proc Natl Acad Sci U S A (1992) 1.21
Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours. Br J Cancer (2006) 1.20
Geographic and patient variation among Medicare beneficiaries in the use of follow-up testing after surgery for nonmetastatic colorectal carcinoma. Cancer (1999) 1.19
Racial disparity in the incidence and case-fatality of colorectal cancer: analysis of 329 United States counties. Cancer Epidemiol Biomarkers Prev (1997) 1.19
How good is prediction of protein structural class by the component-coupled method? Proteins (2000) 1.18
Squamous-lined cysts of the pancreas: lymphoepithelial cysts, dermoid cysts (teratomas), and accessory-splenic epidermoid cysts. Semin Diagn Pathol (2000) 1.17
A national population-based study of incidence of colorectal cancer and age. Implications for screening in older Americans. Cancer (1995) 1.12
Risk of stroke in patients with atrial flutter. Am J Cardiol (2001) 1.12
The N-terminal domain of p73 interacts with the CH1 domain of p300/CREB binding protein and mediates transcriptional activation and apoptosis. Mol Cell Biol (2000) 1.12
Synchronous occurrence of epithelial and stromal tumors in the stomach. Arch Pathol Lab Med (2001) 1.10
Cerebral arterial aneurysm formation and rupture in 20,767 elderly patients: hypertension and other risk factors. J Neurosurg (1995) 1.08
IL-17 and Regulatory Cytokines (IL-10 and IL-27) in L. braziliensis Infection. Parasite Immunol (2011) 1.07
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer (2007) 1.05
Schilder's disease. Sex-linked recessive transmission with specific adrenal changes. Arch Neurol (1972) 1.05
Prevalence of Burkholderia pseudomallei in Guangxi, China. Epidemiol Infect (2009) 1.05
Possible pandemic threat from new reassortment of influenza A(H7N9) virus in China. Euro Surveill (2014) 1.04
Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol (2000) 1.03
Amelogenin-mediated regulation of osteoclastogenesis, and periodontal cell proliferation and migration. J Dent Res (2006) 1.02
Endoscopic diagnosis of laryngeal cancer and precancerous lesions by narrow band imaging. J Laryngol Otol (2010) 1.02
Delayed leaks and fistulas after esophagogastrectomy: radiologic evaluation. AJR Am J Roentgenol (1993) 1.01
Clinical-pathologic study of early breast cancer treated by primary radiation therapy. J Clin Oncol (1983) 1.01
Single intra-articular injection of adeno-associated virus results in stable and controllable in vivo transgene expression in normal rat knees. Osteoarthritis Cartilage (2011) 1.01
Bone-marrow transplantation for metachromatic leucodystrophy. Lancet (1985) 1.00
Activating transcription factor 3 up-regulated by c-Jun NH(2)-terminal kinase/c-Jun contributes to apoptosis induced by potassium deprivation in cerebellar granule neurons. Neuroscience (2007) 1.00
Stimulation of human monocytes with macrophage colony-stimulating factor induces a Grb2-mediated association of the focal adhesion kinase pp125FAK and dynamin. Proc Natl Acad Sci U S A (1995) 0.99
Lack of gender and racial differences in surgery and mortality in hospitalized Medicare beneficiaries with bleeding peptic ulcer. J Gen Intern Med (1997) 0.99
Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody. Clin Cancer Res (1999) 0.99
Free ammonia and free nitrous acid inhibition on the anabolic and catabolic processes of Nitrosomonas and Nitrobacter. Water Sci Technol (2007) 0.98
Identification and characterization of a novel transcription factor participating in the expression of eukaryotic initiation factor 2 alpha. J Biol Chem (1989) 0.98
Post-transcriptional regulation of granulocyte-macrophage colony-stimulating factor synthesis in murine T cells. J Immunol (1990) 0.98
Chromosomal transformation in donor cells following allogeneic bone marrow transplantation. Bone Marrow Transplant (2004) 0.98
Isolation and characterization of the promoter and flanking regions of the gene encoding the human protein-synthesis-initiation factor 2 alpha. Gene (1989) 0.97
A bone morphogenetic protein subfamily: chromosomal localization of human genes for BMP5, BMP6, and BMP7. Genomics (1992) 0.97
A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery. Gene Ther (2009) 0.97
Hurler syndrome with special reference to histologic abnormalities of the growth plate. Clin Orthop Relat Res (1991) 0.95
The regulation of muscle glycogen: the granule and its proteins. Acta Physiol (Oxf) (2010) 0.95
Oxidative enzymes in spinal motor neurons in Werdnig-Hoffmann disease. A comparison with the axonal reaction. Neurology (1966) 0.95
Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study. Gynecol Oncol (2009) 0.95
HIV-specific immunity following immunization with HIV synthetic envelope peptides in asymptomatic HIV-infected patients. AIDS (1999) 0.95
Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol (2009) 0.95
Amoxicillin middle ear fluid penetration and pharmacokinetics in children with acute otitis media. Pediatr Infect Dis J (1998) 0.94
High-precision U-series dating of Locality 1 at Zhoukoudian, China. J Hum Evol (2001) 0.94
Nucleotide regulation and characteristics of potassium channel opener binding to skeletal muscle membranes. Mol Pharmacol (1997) 0.94
Prediction of the hip joint centre in adults, children, and patients with cerebral palsy based on magnetic resonance imaging. J Biomech (2006) 0.93
Case report 377: Intraosseous lipoma (angiolipoma) of right third rib. Skeletal Radiol (1986) 0.93
Comparison between bone marrow transplantation and antithymocyte globulin in treatment of young patients with severe aplastic anemia. J Pediatr (1984) 0.93
Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study. Radiology (2001) 0.93
Concentrations of calcitonin and catecholamines in pheochromocytomas, a mucosal neuroma and medullary thyroid carcinoma. J Clin Endocrinol Metab (1973) 0.92
Parathyroid hormone and mechanical usage have a synergistic effect in rat tibial diaphyseal cortical bone. J Bone Miner Res (1999) 0.92
The use of pathologic features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg (1985) 0.91
Mortality rates, hospital length of stay, and the cost of treating subarachnoid hemorrhage in older patients: institutional and geographical differences. J Neurosurg (1997) 0.91
Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated ovarian epithelial malignancies: a Gynecologic Oncology Group study. J Clin Oncol (1997) 0.91
Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin in advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol (2001) 0.90
Enhanced antitumor effect of cisplatin in human NSCLC cells by tumor suppressor LKB1. Cancer Gene Ther (2012) 0.90
Causes of failure among cuspal-coverage amalgam restorations: a clinical survey. J Am Dent Assoc (2000) 0.90
Systemic human antisense therapy begins. Antisense Res Dev (1992) 0.90
Efficient inhibition of B-cell lymphoma xenografts with a novel recombinant fusion protein: anti-CD20Fab-LDM. Gene Ther (2010) 0.89
Resistance to fracture of teeth with various preparations for amalgam. J Dent (1996) 0.89
Spindle cell tumors associated with mycobacteria in lymph nodes of HIV-positive patients: 'Kaposi sarcoma with mycobacteria' and 'mycobacterial pseudotumor'. Am J Surg Pathol (1999) 0.89
Colorectal carcinoma screening attitudes and practices among primary care physicians in counties at extremes of either high or low cancer case-fatality. Cancer (1999) 0.88
Effect of bioaggregate on differentiation of human periodontal ligament fibroblasts. Int Endod J (2010) 0.88
Radiation-induced changes in the breast. Hum Pathol (1984) 0.88